Skip to content
AnalystLens

BridgeBio Pharma 8-K Report, Financial Results (Aug 5, 2025)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed August 5, 2025
Period End
August 5, 2025
Security
BBIO
In the record · 2019–202610-K710-Q238-K107

BBIO filed 7 annual reports (10-K), 23 quarterly reports (10-Q) and 107 current reports (8-K) between 2019 and 2026.

  1. Leadership change8-K · Feb ’20Feb ’20
  2. Leadership change8-K · Oct ’21Oct ’21
  3. Material agreement8-K · Sep ’23Sep ’23
  4. Material agreement8-K · Aug ’26Aug ’26

Summary

Summary of the 8-K filed August 5, 2025. Cited figures are marked; the original filing is the authoritative source.

BridgeBio Pharma, Inc. (Nasdaq: BBIO) reported financial results for the second quarter ended June 30, 2025, in a press release furnished as Exhibit 99.1 to this Form 8-K under Item 2.02.

Total revenues, net were $110.6 milliona for the quarter, comprised of $71.5 million of U.S. Attruby net product revenue, $1.6 million of royalty revenue, and $37.5 million of license and services revenue. The quarter's license and services revenue included a $30.0 million regulatory milestone from Alexion tied to pricing approval of BEYONTTRA in Japan. Operating costs and expenses rose to $244.8 million from $177.7 million, driven by a $69.6 million increase in selling, general and administrative expenses supporting the Attruby launch.

The net loss attributable to common stockholders of BridgeBio was $181.9 millionb, or $0.95 per share, compared with $73.5 million, or $0.39 per share, a year earlier. The company ended the quarter with $756.9 million in cash, cash equivalents and marketable securities. The filing attributes the increase from $681.1 million at December 31, 2024 primarily to $563.0 million of net proceeds from the 2031 Notes issued in February 2025 and $297.0 million of net proceeds from a royalty interest sale to HealthCare Royalty and Blue Owl Capital in June 2025.

These were partly offset by $279.9 millionc of net cash used in operating activities for the first half of 2025 and repayment of $459.0 million under the prior term loan. The company reported 3,751 unique Attruby prescriptions written by 1,074 prescribers as of August 1, 2025.

The release outlines pipeline catalysts: topline results from the FORTIFY Phase 3 study of BBP-418 and the CALIBRATE Phase 3 study of encaleret, both expected in fall 2025, and topline results from the PROPEL 3 Phase 3 study of infigratinib in achondroplasia, expected in early 2026. Management described the next six months as transformative, with Phase 3 readouts across ADH1, LGMD2I/R9, and achondroplasia.

Key Highlights

  1. Total revenues, net of $110.6 million for Q2 2025, versus $2.2 million in Q2 2024, including $71.5 million of U.S. Attruby net product revenue
  2. Q2 2025 license and services revenue of $37.4 million included a $30.0 million regulatory milestone from Alexion for BEYONTTRA pricing approval in Japan
  3. Operating costs and expenses of $244.8 million, up $67.1 million year over year, mainly from a $69.6 million rise in SG&A tied to the Attruby launch
  4. Net loss attributable to common stockholders of $181.9 million ($0.95 per share) for Q2 2025, compared with $73.5 million ($0.39 per share) in Q2 2024
  5. Cash, cash equivalents and marketable securities of $756.9 million as of June 30, 2025, up from $681.1 million at December 31, 2024
  6. Attruby had 3,751 unique prescriptions from 1,074 prescribers as of August 1, 2025, with the company describing an accelerating launch
  7. Phase 3 readouts expected: FORTIFY (BBP-418) and CALIBRATE (encaleret) in fall 2025, and PROPEL 3 (infigratinib) in early 2026

Frequently Asked Questions

  1. What drove the increase in BridgeBio's second-quarter revenue?

    Total revenues, net rose to $110.6 million from $2.2 million a year earlier. The filing attributes the increase to a $71.5 million increase in net product revenue from Attruby, a $35.3 million increase in license and services revenue (largely a $30.0 million regulatory milestone from Alexion for BEYONTTRA pricing approval in Japan), and a $1.6 million increase in royalty revenue.

  2. Why did operating expenses and the net loss increase?

    Operating costs and expenses rose $67.1 million to $244.8 million, primarily because selling, general and administrative expenses increased $69.6 million, which the filing says reflects investments in the commercial launch and ongoing activities of Attruby. Research and development expenses decreased $3.5 million, mainly due to the 2024 divestiture of two early-stage R&D affiliates. Total other expense, net was $47.4 million, including $37.6 million of interest expense, which pushed the net loss attributable to common stockholders to $181.9 million.

  3. How did BridgeBio fund its cash position in the first half of 2025?

    Cash, cash equivalents and marketable securities increased $75.8 million to $756.9 million. The filing cites $563.0 million of net proceeds from the 2031 Notes issued in February 2025 and $297.0 million of net proceeds from a royalty interest sale to HealthCare Royalty and Blue Owl Capital in June 2025. These were partly offset by $279.9 million of net cash used in operating activities, $459.0 million of term loan repayment, and $48.3 million of common stock repurchases.

  4. What are the near-term clinical catalysts?

    The company expects topline results from the FORTIFY Phase 3 study of BBP-418 for LGMD2I/R9 and the CALIBRATE Phase 3 study of encaleret for ADH1 in fall 2025. Topline results from the PROPEL 3 Phase 3 study of infigratinib for achondroplasia are expected in early 2026. New ATTRibute-CM analyses for Attruby are to be presented at the ESC Congress in August 2025.

  5. How is the Attruby launch progressing?

    As of August 1, 2025, Attruby prescriptions totaled 3,751 unique patient prescriptions written by 1,074 unique prescribers since FDA approval in November 2024. The company described the launch as accelerating, driven by strong month-over-month growth in the treatment-naïve patient segment, and Attruby net product revenue for the quarter was $71.5 million.